Eileen M. Boyle retweeted
Very proud of my friend Prof Ali Bazarbachi, a newly elected member of the national academy of medicine in France. @AUBMC_Official @DrFadloKhuri @TheIACH @TheEBMT @HTLVnet
Eileen M. Boyle retweeted
Less than a week left to submit abstracts for the 3rd London Quantitative Immunology Day! qimmuno.com/ldnday/.
Register and share your work with a diverse set of biologists, physicists, mathematicians all united by a common interest in immunology.
@UDemael
Eileen M. Boyle retweeted
Our session on cancer evolution is chaired by Dr Elise Rees @ekvrees and Prof Francesca Ciccarelli @fcicca. Kane Foster @KaneFos has presented his work on the blood-cancer immunity cycle: learning from multiple-myeloma disease evolution. #CRUKCoL2025
Eileen M. Boyle retweeted
Evolution of the NK-cell compartment in multiple myeloma and role for bone marrow resident CD56bright NK cells with impaired cytotoxicity in promoting immune evasion @ekvrees @EileenMBoyle
doi.org/10.1101/2025.02.26.6…
Eileen M. Boyle retweeted
For Rare Disease Day this Friday, we spoke with @DrSarahGooding, a clinician scientist in @Chapman_lab_UK at the MRC WIMM researching multiple myeloma, a currently incurable type of bone marrow cancer that desperately requires friendlier therapies.
Watch: youtu.be/-H16Wd443EI
Eileen M. Boyle retweeted
The lovely Orla McCourt of @uclh stopped by at #CART25 to share insight into a single-center experience of implementing physiotherapist-led prehabilitation for #CARTCell therapy.
Click here to learn more:
👉 ow.ly/ZEtn50UYCM5
#ImmunoOnc #HemOnc @TheEBMT @EHA_Hematology
Eileen M. Boyle retweeted
🌟 Congratulations to Dr. Éliane Gluckman
on receiving the 2024 Wallace H. Coulter Award
for Lifetime Achievement in Hematology at #ASH24!
A true pioneer in advancing hematology and transforming lives worldwide.
youtube.com/watch?v=iqCB8eGl…
@ElianeGluckman @Mohty_EBMT
Eileen M. Boyle retweeted
Very pleased to have presented the first results of our UKMRA ProMMise trial at #ASH24. Showing a response rate of 88% for Belamaf 1.9mg/kg Q8w plus oral weekly cyclophosphamide in relapsed myeloma with median 3 prior lines.
@LeedsCTRU @MyelomaUK #mmsm
Eileen M. Boyle retweeted
Understanding barriers to enrolment into clinical trials in the UK. Results of a national survey of healthcare professionals and patients. @SelinaChavda @SandraQuinnMonk @misscrhughes @PinkieChambers #ASH24 #mmsm
Eileen M. Boyle retweeted
Researchers at the Crick and @UCL have developed an algorithm that can identify which cell populations within a tumour are growing the fastest.
The findings are part of the @CR_UK-funded TRACERx study and were overseen by @CharlesSwanton and @ZaccaSimo
crick.ac.uk/news-and-reports…
Eileen M. Boyle retweeted
Amazing to see my good friend and a world top expert in #MMsm & transplant & @TheIACH founder dr @Mohty_EBMT being recognized with a very well deserved the @KHCFKHCC life achievement award
Eileen M. Boyle retweeted
My brother-from-another mother and the kindest human and smartest doctor, and easily the number 1 renal oncologist in the world @DrChoueiri from @DanaFarberNews receiving a life achievement award at @KHCFKHCC annual celebration #ArabCancerResearch
Eileen M. Boyle retweeted
Very well deserved recognition of a true role model and one of the most supportive mentors! Congratulations @Mohty_EBMT
This quoted post is unavailable.
Eileen M. Boyle retweeted
For every £1 of public money invested in the higher education sector, £14 goes back into the economy.
Universities power economic growth all over the UK. The government must invest in them to drive the growth mission.
See more on the impact of unis👇
loom.ly/T-7pw68
Eileen M. Boyle retweeted
After an excellent meeting on Waldenstrom put together by Steve and Chris, Dylan Gagler receives his young investigator award
Eileen M. Boyle retweeted
We @at_Mitralab and myself are happy to announce the opening of the 8th edition of the international symposium CARTday. We’re going to have 2-day intensive discussions with experts from all over the world.
Eileen M. Boyle retweeted
The criteria for identifying patients with high-risk #MultipleMyeloma has recently been updated!🩸
Hear from @FaithEDavies1 of @nyulangone who outlines the changes:
👉 ow.ly/PlEM50TE9j6 👈
#MMSM #Myeloma #HemOnc @Myeloma_Society
Eileen M. Boyle retweeted
Great start of day 2 of #ESHMM2024 @ESHaematology with @_DrCP setting the scene on frailty biomarkers in older #myeloma patients in session chaired by @H_Einsele @myelomaMD #MMsm
Eileen M. Boyle retweeted
Does HDM+ASCT still have a role in frontline MM treatment for all eligible patients? @Mohty_EBMT discusses this important question. Should MRD or high-risk status drive our decision? #ESHMM2024 #ESHCONFERENCES #MMsm


































